NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
6 trialsNCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03773666 2022-09-13
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03430895 2021-12-01
Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03534492 2020-04-06
NEODURVARIB
Spanish Oncology Genito-Urinary Group
Phase 2 Completed